JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production

Arthritis and Rheumatism

Volumn 64, Issue 11, 2012, Pages 3531-3542

  Labranche, Timothy P ^a   Jesson, Michael I ^a   Radi, Zaher A ^a   Storer, Chad E ^a   Guzova, Julia A ^a   Bonar, Sheri L ^a   Thompson, Janice M ^a   Happa, Fernando A ^a   Stewart, Zachary S ^a   Zhan, Yutian ^a   Bollinger, Chris S ^a   Bansal, Prashant N ^a   Wellen, Jeremy W ^a   Wilkie, Dean P ^a   Bailey, Steven A ^a   Symanowicz, Peter T ^a   Hegen, Martin ^a   Head, Richard D ^a   Kishore, Nandini ^a   Mbalaviele, Gabriel ^a   Meyer, Debra M ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CHLORDANE; COLLAGEN; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; TOFACITINIB;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; EDEMA; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY CELL; JOINT INJURY; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RAT; T LYMPHOCYTE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; JANUS KINASES; MACROPHAGES; MONOCYTES; OSTEOCLASTS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RANK LIGAND; RATS; RATS, INBRED LEW; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84867077631     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34649     Document Type: Article

References (46)

1. Christodoulou C, Choy EH,. Joint inflammation and cytokine inhibition in rheumatoid arthritis. Clin Exp Med 2006; 6: 13-9.
2. O'Shea JJ,. Targeting the Jak/STAT pathway for immunosuppression. Ann Rheum Dis 2004; 63 Suppl II: ii67-71.
3. Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010; 7: 41.
4. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-32.
5. Flanagan ME, Blumenkopf TA, Brissette WH, Brown MF, Casavant JM, Shang-Poa C, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 2010; 53: 8468-84.
6. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011; 186: 4234-43.
7. West K,. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Investig Drugs 2009; 10: 491-504.
8. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo [published erratum appears in Arthritis Rheum 2012;64:1487]. Arthritis Rheum 2009; 60: 1895-905.
9. Borie DC, O'Shea JJ, Changelian PS,. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. Trends Mol Med 2004; 10: 532-41.
10. O'Shea JJ, Gadina M, Schreiber RD,. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002; 109 Suppl: S1231.
11. Pesu M, Candotti F, Husa M, Hofmann SR, Notarangelo LD, O'Shea JJ,. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 2005; 203: 127-42.
12. Milici AJ, Kudlacz EM, Audoly L, Zwillich S, Changelian P,. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 2008; 10: R14.
13. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH, and the Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011; 63: 1150-8.
14. Van der Heijde D, Tanaka Y, Fleischmann R, Keystone EC, Kremer JM, Zerbini CA, et al, and the ORAL Scan investigators. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: a 24-month phase 3 study [abstract]. Arthritis Rheum 2011; 63 Suppl: S1017-8.
15. Hegen M, Keith JC Jr, Collins M, Nickerson-Nutter CL,. Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1505-15.
16. Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S, Goto T,. Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis. J Rheumatol 2003; 30: 2193-200.
17. Bendele AM, McComb J, Gould T, Frazier J, Chlipala ES, Seely J, et al. Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats. Inflamm Res 1999; 48: 453-60.
18. Bendele A, McComb J, Gould T, McAbee T, Sennello G, Chlipala E, et al. Animal models of arthritis: relevance to human disease. Toxicol Pathol 1999; 27: 134-42.
19. Lin TH, Hegen M, Quadros E, Nickerson-Nutter CL, Appell KC, Cole AG, et al. Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice. Arthritis Rheum 2010; 62: 2283-93.
20. LaBranche TP, Hickman-Brecks CL, Meyer DM, Storer CE, Jesson MI, Shevlin KM, et al. Characterization of the KRN cell transfer model of rheumatoid arthritis (KRN-CTM), a chronic yet synchronized version of the K/BxN mouse. Am J Pathol 2010; 177: 1388-96.
21. Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ, et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000; 43: 2648-59.
22. Marshak DR, Greenwalt DE,. Differentiating primary human cells in rapid-throughput discovery applications. Methods Mol Biol 2007; 356: 121-8.
23. Damoiseaux JG, Dopp EA, Calame W, Chao D, MacPherson GG, Dijkstra CD,. Rat macrophage lysosomal membrane antigen recognized by monoclonal antibody ED1. Immunology 1994; 83: 140-7.
24. Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 834-8.
25. Wijbrandts CA, Vergunst CE, Haringman JJ, Gerlag DM, Smeets TJ, Tak PP,. Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: implications for use of synovial sublining macrophages as a biomarker. Arthritis Rheum 2007; 56: 3869-71.
26. Nicolls MR, Aversa GG, Pearce NW, Spinelli A, Berger MF, Gurley KE, et al. Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody. Transplantation 1993; 55: 459-68.
27. McComb J, Gould T, Chlipala E, Sennelo G, Frazier J, Kieft G, et al. Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: correlation of plasma levels with efficacy. J Rheumatol 1999; 26: 1347-51.
28. Mbalaviele G, Anderson G, Jones A, De Ciechi P, Settle S, Mnich S, et al. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction. J Pharmacol Exp Ther 2006; 317: 1044-53.
29. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003; 302: 875-8.
30. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93: 385-95.
31. Skerry TM, Suva LJ,. Investigation of the regulation of bone mass by mechanical loading: from quantitative cytochemistry to gene array. Cell Biochem Funct 2003; 21: 223-9.
32. Blair HC, Athanasou NA,. Recent advances in osteoclast biology and pathological bone resorption. Histol Histopathol 2004; 19: 189-99.
33. Radi ZA, Guzman RE, Bell RR,. Increased connective tissue extracellular matrix in the op/op model of osteopetrosis. Pathobiology 2009; 76: 199-203.
34. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998; 95: 3597-602.
35. Teitelbaum SL,. Bone resorption by osteoclasts. Science 2000; 289: 1504-8.
36. Wong PK, Quinn JM, Sims NA, van Nieuwenhuijze A, Campbell IK, Wicks IP,. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 2006; 54: 158-68.
37. Horwood N,. Lymphocyte-derived cytokines in inflammatory arthritis. Autoimmunity 2008; 41: 230-8.
38. Poubelle PE, Chakravarti A, Fernandes MJ, Doiron K, Marceau AA,. Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils. Arthritis Res Ther 2007; 9: R25.
39. Yeo L, Toellner KM, Salmon M, Filer A, Buckley CD, Raza K, et al. Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis 2011; 70: 2022-8.
40. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-65.
41. Djaafar S, Pierroz DD, Chicheportiche R, Zheng XX, Ferrari SL, Ferrari-Lacraz S,. Inhibition of T cell-dependent and RANKL-dependent osteoclastogenic processes associated with high levels of bone mass in interleukin-15 receptor-deficient mice. Arthritis Rheum 2010; 62: 3300-10.
42. Weitzmann MN, Cenci S, Rifas L, Brown C, Pacifici R,. Interleukin- 7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood 2000; 96: 1873-8.
43. Kwok SK, Cho ML, Park MK, Oh HJ, Park JS, Her YM, et al. Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis. Arthritis Rheum 2012; 64: 740-51.
44. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 2000; 408: 600-5.
45. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304-9.
46. Hashizume M, Hayakawa N, Mihara M,. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17. Rheumatology (Oxford) 2008; 47: 1635-40.